Editorial on Sramkova et al., "Apolipoprotein M: a novel adipokine decreasing with obesity and upregulated by calorie restriction".
Editorial on Sramkova et al., "Apolipoprotein M: a novel adipokine decreasing with obesity and upregulated by calorie restriction".
复制标题
Sramkova 等人的社论，“载脂蛋白 M：一种新型脂肪因子，随肥胖而减少，并因热量限制而上调”。
DOI：
10.1093/ajcn/nqz053
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
Tso,Patrick
中科院分区：
文献类型：
--
作者：
Ko,Chih-Wei;Qu,Jie;Tso,Patrick
在本期杂志中，Sramkova等人发表了来自5项独立临床试验的新数据，以及一项使用人类多能脂肪源性干细胞（hMADS）脂肪细胞的体外研究(1)。本研究的目的是确定载脂蛋白M （apo M）与其参与代谢综合征和胰岛素敏感性之间的关系。在一项有吸引力的补充离体研究中，作者检查了脂肪组织在热量限制和体重减轻期间对载脂蛋白M表达和分泌的调节。本研究的意义在于：1)大多数关于载脂蛋白M的研究都是在肝脏和肾脏中进行的（2-4），但我们对载脂蛋白M在人体脂肪组织中的功能知之甚少；2)这是一个有益的例子，说明跨学科研究如何在我们对人体脂肪组织载脂蛋白M的生理和功能的理解方面取得重大进展；3)与其他优秀的研究一样，本研究的完成不仅大大提高了我们对人体脂肪组织载脂蛋白M产生和分泌的认识，而且激发了我们提出更多的问题，如载脂蛋白M如何影响胰岛素敏感性，以及肝、肾和脂肪组织的载脂蛋白M产生和分泌之间的关系和相互作用。基于对从人类脂肪组织中分离的脂肪细胞和基质血管细胞的条件培养基的微阵列和蛋白质组学分析的结合，作者确定了载脂蛋白M是一种新的脂肪因子。然后，研究人员通过检测皮下腹部脂肪组织中动脉血和静脉血载脂蛋白M的差异浓度，进一步验证了脂肪组织中载脂蛋白M的分泌。这些观察提供了第一个证据，证明载脂蛋白M是由肝脏和肾脏以外的组织产生和分泌的。尽管肝脏产生的载脂蛋白M明显多于脂肪组织，但研究人员提出了令人信服的证据，证明脂肪组织中载脂蛋白M的表达与肥胖及其合并症（如代谢综合征和2型糖尿病）呈负相关。
In this issue of the Journal, Sramkova et al. present novel data from 5 separate clinical trials as well as an in vitro study that uses human multipotent adipose-derived stem cell (hMADS) adipocytes (1). The goal of this study was to determine the relation between apolipoprotein M (apo M) and its participation in metabolic syndrome and insulin sensitivity. In an appealing complementary ex vivo study, the authors examined the regulation of apo M expression and secretion by adipose tissue during caloric restriction and resulting weight loss. This study is significant for the following reasons: 1) most studies on apo M have been conducted in the liver and kidney (2–4), but we know very little of apo M function in human adipose tissue; 2) this is a helpful example of how interdisciplinary studies can lead to a major advancement in our understanding of the physiology and function of human adipose tissue apo M; and 3) as with other outstanding research, the completion of this study not only greatly enhances our knowledge of human adipose tissue apo M production and secretion, but also stimulates us to ask additional questions, such as how apo M affects insulin sensitivity and what the relation and interaction are between apo M production and secretion by the liver, kidney, and adipose tissue.Based on the use of a combination of microarray and proteomic analyses of the conditioned media from adipocytes and stromal vascular cells isolated from human adipose tissue, the authors identified apo M as a novel adipokine. The investigators then further validated apo M secretion from adipose tissue by detecting differential concentrations of apo M between arterial and venous blood in the subcutaneous abdominal adipose tissue. These observations provide the first evidence that apo M is produced and secreted by a tissue other than the liver and kidney. Although the liver produces significantly more apo M than the adipose tissue, the investigators present compelling evidence demonstrating that apo M expression in adipose tissue is inversely associated with obesity and its comorbidities such as metabolic syndrome and type 2 diabetes.